A deliberate third-party attempt to mislead investors and the market
In the volatile intersection of financial markets and digital misinformation, Lantern Pharma found itself the target of a fabricated report claiming its CEO had departed — a lie that erased nearly half the company's market value in a single day. The incident, unfolding in late March 2026, speaks to a recurring vulnerability in modern markets: that truth, however swiftly deployed, must race to catch a rumor that travels at the speed of algorithmic reaction. Lantern's board moved decisively to affirm CEO Panna Sharma's continued leadership, while signaling that the episode may have been not mere carelessness, but deliberate manipulation.
- A false report claiming Lantern Pharma's CEO was departing sent the stock crashing 45% in a single session, wiping out nearly half its market value before the company could respond.
- The board's language was pointed and deliberate — calling the fabricated article a calculated attempt to deceive investors, not a misunderstanding or rumor run wild.
- Suspicious trading patterns around the false report's publication raised the specter of a coordinated short-selling scheme, prompting the company to investigate potential market manipulation.
- Lantern is pursuing legal remedies and considering regulatory referrals, signaling it intends to treat this as a serious financial crime rather than a reputational inconvenience.
- CEO Panna Sharma is scheduled to appear live on an investor webcast days after the incident — his presence itself serving as the most direct rebuttal to the lie that briefly unseated him.
On the morning of March 28, 2026, Lantern Pharma moved swiftly to contain the fallout from a fabricated report that had already done significant damage. The false claim — that CEO Panna Sharma was leaving the company — had sent the stock into freefall the previous day, erasing nearly 45 percent of its value in a single session, dropping from roughly $2.08 to $1.15 per share.
Lantern, an AI-driven oncology firm built around its RADR platform for accelerating cancer drug development, issued a firm rebuttal: Sharma remained president, CEO, and board director, fully engaged in operations and strategy, with no intention to resign. To underscore the point, he was scheduled to lead an earnings webcast just days later — a public appearance designed to put the rumor to rest through his own visible presence.
Board chairman Donald Jeff Keyser went further, expressing full confidence in Sharma's leadership and citing recent milestones, including clearance of an investigational new drug application for a pediatric cancer trial. But his statement carried unmistakable anger. The board was 'disturbed' by what it described as a deliberate third-party effort to deceive investors — language that implied something far more calculated than ordinary gossip.
The speed and severity of the stock's collapse raised immediate questions about coordination. Lantern announced an investigation into the report's origin and any trading activity that may have surrounded its publication, and signaled its intent to pursue legal action and potential regulatory referral. Investors were urged to rely only on official communications, a reminder that in an era of instant information and algorithmic trading, a well-timed lie can move markets faster than truth can follow.
On the morning of March 28, 2026, Lantern Pharma moved quickly to contain damage from a rumor that had already cost the company dearly. A false report claiming CEO Panna Sharma was departing had sent the stock into freefall the previous day, erasing nearly 45 percent of its value in a single session. The company's response was unambiguous: Sharma was staying, the report was fabricated, and someone would answer for it.
Lantern, an artificial intelligence-driven oncology firm built around its proprietary RADR platform for accelerating cancer drug development, issued a statement reaffirming Sharma's position as president, chief executive, and board director. He remained fully engaged in the company's operations and strategic direction, the statement said, with no intention to resign and no request to do so from the board. The timing was precise: Sharma would lead a scheduled earnings webcast four days later to discuss fourth-quarter and full-year 2025 results, a public appearance designed to put the rumor to rest.
Donald Jeff Keyser, the board chairman, went further. He expressed the board's full confidence in Sharma's leadership and highlighted recent achievements—the clearance of an investigational new drug application for a pediatric cancer trial and continued expansion of the company's AI capabilities. But Keyser's statement carried an edge of anger. The board was "disturbed" by what it characterized as a deliberate third-party attempt to deceive investors and manipulate the market. The language suggested this was not mere gossip but something more calculated.
The stock's collapse—from roughly $2.08 to $1.15 per share—had been swift and severe. That kind of movement in response to a single unverified claim raised obvious questions about coordination. Had someone shorted the stock before releasing the false report? Had trading activity spiked in ways that suggested foreknowledge? Lantern announced it was investigating the origin and spread of the fabricated article, including any coordinated trading surrounding its publication. The company signaled its intent to pursue legal remedies and was considering referral to regulatory authorities—a clear warning that this would not be treated as a minor embarrassment.
For investors, the company issued a broader caution: be skeptical of third-party reports, rely only on official communications through SEC filings and the investor relations website, and understand that bad actors might try to move stock prices through disinformation. It was a reminder that in the age of instant information and algorithmic trading, a well-timed lie could move markets faster than truth could catch up.
The webcast on March 30 would serve multiple purposes. Sharma would present the company's actual financial and operational performance. Management would update investors on clinical programs and the evolution of the RADR platform. And his presence, speaking directly to shareholders, would be its own form of evidence—a living refutation of the rumor that had briefly shaken confidence in the company's leadership. The investigation into who had planted the false report and why would continue in the background, but the immediate task was to restore trust and move forward.
Citas Notables
The Board has full confidence in Panna Sharma's leadership. We are disturbed by what appears to be a deliberate third-party attempt to mislead investors and the market.— Donald Jeff Keyser, Chairman of Lantern's Board of Directors
La Conversación del Hearth Otra perspectiva de la historia
Why would someone go to the trouble of fabricating a CEO departure rumor? What's the financial incentive?
If you short a stock—bet that it will fall—and then release a credible-sounding false report that tanks the price, you profit enormously. A 45 percent drop in a single day is the kind of move that makes money for people positioned on the right side of it. That's likely why Lantern is investigating coordinated trading activity around the report's release.
But wouldn't that be obvious? Wouldn't regulators catch it?
Eventually, maybe. But in the moment, the market moves on information, real or not. By the time investigators trace the report back to its source and prove coordination, the perpetrator has already cashed out. That's why Lantern is being aggressive about referring this to authorities—they want to establish a pattern and make an example.
The CEO is going on a webcast in four days. Isn't that risky? What if something goes wrong?
It's actually the opposite. His presence, speaking directly to shareholders about real results and real progress, is the antidote to the rumor. Silence would fuel speculation. A public appearance by Sharma, discussing the company's actual performance and pipeline, is the most credible way to reset the narrative.
What does this say about the company's security? How did a false report get out in the first place?
That's the question Lantern is trying to answer. It suggests either someone with inside knowledge fabricated a convincing story, or the report was sophisticated enough to fool people who should have known better. Either way, it exposed a vulnerability in how information flows through markets and how quickly false claims can move stock prices.